Those that were statistically significant included EFNS criteria, generally the highest (0.68 (p = 0.002) whole cohort, 0.65 (p = 0.04) CIDP-DM patients subgroup, and 0.73 (p = 0.02) CIDP+DM patients), 10% and 30% cut off study criteria for the whole cohort 0.63, and 0.64 (p = 0.02), 10% cut off study criteria for CIDP-DM patients, 0.66 (p = 0.02), and a trend at the 30% cut off study criteria in CIDP+DM patients subgroup 0.7 (p = 0.05). This evidence concerns the gene PMP22 and diabetes mellitus.